

Supplementary Table 1. Subsequent therapy with docetaxel among elderly and younger subgroups (intent-to-treat population)

	Elderly (≥ 75 years)		Younger (< 75 years)	
	Abiraterone-prednisone (<i>n</i> = 185)	Prednisone alone (<i>n</i> = 165)	Abiraterone-prednisone (<i>n</i> = 361)	Prednisone alone (<i>n</i> = 377)
Subsequent therapy with docetaxel, n (%)	59 (31.9)	68 (41.2)	180 (49.9)	236 (62.6)
No subsequent therapy with docetaxel, n (%)	126 (68.1)	97 (58.8)	181 (50.1)	141 (37.4)

Supplementary Table 2. Adverse events reported during treatment, by 3 age categories (safety population)

	≥75 years				65–74 years				<65 years			
	Abiraterone- prednisone (n=182)		Prednisone alone (n=164)		Abiraterone- prednisone (n=225)		Prednisone alone (n=222)		Abiraterone- prednisone (n=135)		Prednisone alone (n=154)	
	Grades 1-4	Grades 3/4	Grades 1-4	Grades 3/4	Grades 1-4	Grades 3/4	Grades 1-4	Grades 3/4	Grades 1-4	Grades 3/4	Grades 1-4	Grades 3/4
Subjects with TEAE, n (%)	182 (100.0)	104 (57.1)	163 (99.4)	92 (56.1)	223 (99.1)	109 (48.4)	214 (96.4)	88 (39.6)	133 (98.5)	54 (40.0)	147 (95.5)	55 (35.7)
TEAE leading to death, n (%)	14 (7.7)		9 (5.5)		5 (2.2)		5 (2.3)		2 (1.5)		2 (1.3)	

TEAE = treatment-emergent adverse event.

